Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer